This study’s identification of low-CpG ITR mutants within the JL transposon system, combined with CpG-free CAR genes and promoters, has led to the development of CAR-T cells with improved anti-tumor activity, offering new avenues for gene therapy and genetic tool development. This evidence concerns the gene GPR180 and neoplasm.